vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $71.1M, roughly 1.2× RE/MAX Holdings, Inc.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -4.7%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
IOVA vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $71.1M |
| Net Profit | — | $1.4M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 13.1% |
| Net Margin | — | 2.0% |
| Revenue YoY | 17.7% | -1.8% |
| Net Profit YoY | — | -75.2% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $71.1M | ||
| Q3 25 | $67.5M | $73.2M | ||
| Q2 25 | $60.0M | $72.8M | ||
| Q1 25 | $49.3M | $74.5M | ||
| Q4 24 | $73.7M | $72.5M | ||
| Q3 24 | $58.6M | $78.5M | ||
| Q2 24 | $31.1M | $78.5M | ||
| Q1 24 | $715.0K | $78.3M |
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-91.3M | $4.0M | ||
| Q2 25 | $-111.7M | $4.7M | ||
| Q1 25 | $-116.2M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-83.5M | $966.0K | ||
| Q2 24 | $-97.1M | $3.7M | ||
| Q1 24 | $-113.0M | $-3.4M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 13.1% | ||
| Q3 25 | -140.7% | 25.0% | ||
| Q2 25 | -189.8% | 19.3% | ||
| Q1 25 | -245.8% | 7.2% | ||
| Q4 24 | -117.5% | 5.9% | ||
| Q3 24 | -152.1% | 19.4% | ||
| Q2 24 | -327.6% | 20.6% | ||
| Q1 24 | -16464.6% | 5.8% |
| Q4 25 | — | 2.0% | ||
| Q3 25 | -135.3% | 5.4% | ||
| Q2 25 | -186.2% | 6.4% | ||
| Q1 25 | -235.5% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -142.7% | 1.2% | ||
| Q2 24 | -312.2% | 4.7% | ||
| Q1 24 | -15800.8% | -4.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-0.28 | — | ||
| Q2 24 | $-0.34 | — | ||
| Q1 24 | $-0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $698.6M | $452.4M |
| Total Assets | $913.2M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $118.7M | ||
| Q3 25 | $300.8M | $107.5M | ||
| Q2 25 | $301.2M | $94.3M | ||
| Q1 25 | $359.7M | $89.1M | ||
| Q4 24 | $323.8M | $96.6M | ||
| Q3 24 | $397.5M | $83.8M | ||
| Q2 24 | $412.5M | $66.1M | ||
| Q1 24 | $356.2M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
| Q4 25 | $698.6M | $452.4M | ||
| Q3 25 | $702.3M | $448.1M | ||
| Q2 25 | $698.5M | $442.4M | ||
| Q1 25 | $767.9M | $433.5M | ||
| Q4 24 | $710.4M | $429.5M | ||
| Q3 24 | $773.5M | $423.1M | ||
| Q2 24 | $768.5M | $418.4M | ||
| Q1 24 | $680.0M | $412.0M |
| Q4 25 | $913.2M | $582.5M | ||
| Q3 25 | $904.9M | $582.2M | ||
| Q2 25 | $907.4M | $574.8M | ||
| Q1 25 | $966.7M | $571.4M | ||
| Q4 24 | $910.4M | $581.6M | ||
| Q3 24 | $991.1M | $578.6M | ||
| Q2 24 | $964.3M | $571.4M | ||
| Q1 24 | $869.8M | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $40.9M |
| Free Cash FlowOCF − Capex | $-61.9M | $33.5M |
| FCF MarginFCF / Revenue | -71.3% | 47.1% |
| Capex IntensityCapex / Revenue | 10.7% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $40.9M | ||
| Q3 25 | $-78.7M | $17.7M | ||
| Q2 25 | $-67.4M | $4.6M | ||
| Q1 25 | $-103.7M | $5.7M | ||
| Q4 24 | $-73.3M | $59.7M | ||
| Q3 24 | $-59.0M | $17.6M | ||
| Q2 24 | $-98.4M | $15.9M | ||
| Q1 24 | $-122.3M | $9.4M |
| Q4 25 | $-61.9M | $33.5M | ||
| Q3 25 | $-89.5M | $16.4M | ||
| Q2 25 | $-74.9M | $2.9M | ||
| Q1 25 | $-109.9M | $4.0M | ||
| Q4 24 | $-77.5M | $53.0M | ||
| Q3 24 | $-61.3M | $16.3M | ||
| Q2 24 | $-98.9M | $14.0M | ||
| Q1 24 | $-126.5M | $6.8M |
| Q4 25 | -71.3% | 47.1% | ||
| Q3 25 | -132.7% | 22.4% | ||
| Q2 25 | -124.9% | 4.0% | ||
| Q1 25 | -222.8% | 5.3% | ||
| Q4 24 | -105.1% | 73.2% | ||
| Q3 24 | -104.6% | 20.8% | ||
| Q2 24 | -317.9% | 17.8% | ||
| Q1 24 | -17685.3% | 8.6% |
| Q4 25 | 10.7% | 10.4% | ||
| Q3 25 | 16.1% | 1.8% | ||
| Q2 25 | 12.4% | 2.2% | ||
| Q1 25 | 12.6% | 2.3% | ||
| Q4 24 | 5.7% | 9.1% | ||
| Q3 24 | 3.9% | 1.7% | ||
| Q2 24 | 1.4% | 2.4% | ||
| Q1 24 | 583.4% | 3.3% |
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
